Filing Details

Accession Number:
0001209191-21-070768
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-21 16:08:47
Reporting Period:
2021-12-20
Accepted Time:
2021-12-21 16:08:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434316 Fate Therapeutics Inc FATE Biological Products, (No Disgnostic Substances) (2836) 651311552
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1821530 Iii J Edward Dulac C/O Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego CA 92131
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-20 14,437 $35.52 126,381 No 4 M Direct
Common Stock Disposition 2021-12-20 15,977 $60.00 110,404 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-12-20 14,437 $0.00 14,437 $35.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
128,238 2030-08-17 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.
  2. The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.